Wednesday, 24th of June 2015 |
UPDATE ON VACCINE-DERIVED POLIOVIRUSES WORLDWIDE, JANUARY 2014–MARCH 2015
Excerpt below; full text, with tables, is at http://www.who.int/wer/2011/wer9025.pdf?ua=1
One of the main tools used in polio eradication efforts has been the live, attenuated oral poliovirus vaccine (OPV),2 an inexpensive vaccine easily administered by trained volunteers. Although OPV may require several doses to induce immunity, it provides long-term protection against paralytic poliomyelitis. Through effective use of OPV, the Global Polio Eradication Initiative (GPEI) has brought wild polioviruses to the threshold of eradication. However, rare cases of vaccine-associated paralytic poliomyelitis (VAPP) can occur both among immunologically normal OPV recipients and their contacts and among persons who have primary B-cell immunodeficiencies (PIDs; defects in antibody production).
In addition, circulating vaccine-derived polioviruses (cVDPVs)3 can emerge in areas with low OPV coverage and cause outbreaks of poliomyelitis. Also, immunodeficiency-associated VDPVs (iVDPVs) can replicate for years in some persons with PIDs. This report updates previous surveillance summaries4 and describes VDPVs detected worldwide during January 2014–March 2015.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
43027052 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |